Dermavant Submits Supplemental sNDA to FDA for VTAMA Cream for AD in Adults and Children 2 Years of Age and Older
Dermavant Sciences has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. “We are confident, that VTAMA cream, if approved by the FDA, will be well […]
Head-to-Head Study: EscharEx Bests Santyl for Treating VLUs
MediWound Ltd’s EscharEx bested market leader collagenase Santyl ointment in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU). EscharEx is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds that is currently in the advanced stages of clinical development. […]
Is a Pharmacologic Treatment for Neurofibromatosis Type 1 Skin Tumors on the Horizon?
Current treatment for neurofibromatosis type 1 skin tumors involves monitoring the tumors and removing them surgically if necessary, but this isn’t ideal as neurofibromas can grow back and continue originating in other parts of the body, plus surgery leaves scars. Now, scientists have identified a key player in the protein signature: the GPR68 receptor. When it is activated […]
Barzolvolimab Shows Promise in CSU
Chronic spontaneous urticaria (CSU) is getting a lot of attention these days as researchers close in on the role mast cells play in causing hives. Top-line results from a phase 2 trial show that barzolvolimab (anti-KIT monoclonal antibody) improves symptoms in patients with antihistamine-refractory CSU. “Barzolvolimab successfully decreased disease activity in patients with moderate to […]
For the Win: Cerave Scores Big with SuperBowl Ad
For weeks, actor Michael Cera has been in the news and across social media promoting his ‘namesake’ brand, CeraVe. In the new ad, Cera goes toe-to-toe with dermatologists and reveals his very own Michael CeraVe commercial, but Cera’s bizarre campaign gets debunked by a boardroom of CeraVe dermatologists, who reminded him that CeraVe is and always has […]
On the Horizon: New, Non-invasive Light-based Techniques May Help Detect Skin Cancer in Older Adults
When examined under polarized laser light, ageing skin looks noticeably different than younger skin, and this finding could pave the way for new, non-invasive light-based techniques to detect skin cancer in older individuals. The new study indicates that the altered light scattering properties of ageing skin are largely due to changes in the skin’s texture, […]
Get to Know Alys Pharmaceuticals, Inc.
Alys Pharmaceuticals, Inc. is coming out of the gate strong with $100M financing from Medicxi to advance its immuno-dermatology focused pipeline. Alys combines six asset-centric Medicxi companies including Al Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. Co-founded by Medicxi and several dermatology and scientific experts, including TDD Editorial Advisory Board member John […]
“Comforting and Encouraging” Study Shows JAK Inhibitors Not Linked to Short-Term Heart Woes in Derm Patients
By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology1, the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as […]
One-on-One: TDD Talks to Leo Pharma’s Brian Hilberdink About Chronic Hand Eczema and the Delta Force Trial
Leo Pharma recently reported that delgocitinib cream, an investigational topical pan-JAK inhibitor, demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema (CHE) in the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a […]
AAAAI News: Early Skin Microbiome and Metabolome Signatures May Predict AD in Infants
Early skin microbiome and metabolome signatures can predict atopic dermatitis in infants aged 6 to 18 months old, according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting. The Singapore Preconception Study of Long-Term Maternal and Child Outcomes (S-PRESTO) mother-offspring cohort profiled bacterial metagenomics, antimicrobial peptides (AMPs) […]